Evaluation of Clemastine effects in CTS pateints

Phase 2

Conditions: Carpal tunnel syndrome.
Carpal tunnel syndrome
G56.0

Registration Number: IRCT20190428043404N2

Lead Sponsor: Iran University of Medical Sciences

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Pending

Sex: All

Target Recruitment: 20

Inclusion Criteria

Pain or paresthesia or hypoesthesia in distal hand region or thenar weakness, with positive tinel or phalen tests
No clinical evidence of cervical radiculopathy or radicular pain
Negative history for Carpal Tunnel Release (CTR) surgery
No injection inside or in proximity of carpal tunnel in last 3 months
No present contraindication for Clemastine, such as drug allergy to antihistamine group
Patient is willing to knowingly participate in a clinical trial

Exclusion Criteria

Patient isn't cooperative for questionnaire completion
Drug or alcohol addiction
Major depressive disorder or uncontrolled psychiatric disorders
Positive history for malignancy or infection in wrist or hand region
History of ischemic or neurovascular injury in wrist or hand region
Usage of other treatment measures during trial period
Patient doesn't follow correct treatment plan regarding drug or splint usage

Study & Design

Study Type: interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Patient's pain intensity(Visual Analogue Scale). Timepoint: Before, after one month and after three months of intervention. Method of measurement: Using the Visual Analogue Scale.;Median nerve sensory action potential amplitude. Timepoint: Before, after one month and after three months of intervention. Method of measurement: Nerve conduction study.;Median nerve sensory action potential latency. Timepoint: Before, after one month and after three months of intervention. Method of measurement: Nerve conduction study.;Median nerve motor action potential latency. Timepoint: Before, after one month and after three months of intervention. Method of measurement: Nerve conduction study.;Median nerve motor action potential amplitude. Timepoint: Before, after one month and after three months of intervention. Method of measurement: Nerve conduction study.

Secondary Outcome Measures